Figure S5 from The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma

Figure S5 from The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma

<p>Supplemental Figure 5: Combination therapy of XVir-N-31 and CDK4/6 inhibitor LEE011 induces calreticulin (CALR) surface expression and increases phagocytosis in vitro.</p>

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awdur: Sebastian Johannes Schober (14971891) (author)
Awduron Eraill: Caroline Schoening (14971894) (author), Jennifer Eck (14971897) (author), Charlotte Middendorf (14971900) (author), Julia Lutsch (14971903) (author), Pia Knoch (14971906) (author), Anna Josefine von Ofen (14971909) (author), Hendrik Gassmann (14971912) (author), Melanie Thiede (14971915) (author), Julia Hauer (14971918) (author), Andreas Kolk (14971921) (author), Klaus Mantwill (14971924) (author), Jürgen E. Gschwend (14971927) (author), Stefan E.G. Burdach (14971930) (author), Roman Nawroth (14971933) (author), Uwe Thiel (14971936) (author), Per Sonne Holm (14971939) (author)
Cyhoeddwyd: 2025
Pynciau:
Cancer
Therapeutic Research and Development
Immuno-oncology
Immunotherapy
Combination immunotherapy
Pediatric Cancers
Sarcomas
Translational Research
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg